Zanco Journal of Medical Sciences
Skip Navigation Links
Available Issues
Editorial Board
Information for Authors
Review Process
Links and Contacts
  Zanco J Med Sci:  Aug. 2018; 22 (2): 262-272

Molecular detection of SHV-Type ESBL in E. coli and K.pneumoniae and their antimicrobial resistance profile

Sayran Hamad Haji *, Salah Tofik Jalal **, Sharmin Abdullah Omer *, Ahang Hasan Mawlood **


* Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Erbil, Iraq.

*** Department of Medical Microbiology, College of Health Science, Hawler Medical University, Erbil, Iraq.


Background and objective: The increase in the incidence of Beta-lactam resistance in Gram-negative bacteria has become a main clinical problem worldwide that limits therapeutic options. The production of extended-spectrum blactamases is the major source of resistance to newer beta-lactam antibiotics in Enterobacteriaceae. This study aimed to check the presence of extended-spectrum β-lactamase producing K. pneumoniae and E. coli and the evaluation of ESBL among those isolates.

Methods: A total of 120 E. coli and K. pneumoniae clinical isolates were obtained from Rizgary Teaching Hospital in Erbil City, Iraqi Kurdistan Region, during the first six months of 2016. All isolates were identified and checked for the production of ESBL using Vitek 2 automated system. The technique of PCR was performed for the detection of the presence of blaSHV gene from these isolates. The antibiotic resistant profiles for these isolates were also investigated.

Results: The overall proportion of ESBL-producing E. coli and K. pneumoniae isolates, 77 (76.2%) and 15 (78.9%) isolates were ESBL producers, respectively. ESBL-producing isolates were significantly more resistant than Non-ESBL-producers (P < 0.05). PCR performed on 30 ESBL positive isolates, 21(70%) isolates were of E. coli, and 9 (30%) isolates were of K.pneumoniae. The ESBL B-lactamase related SHV gene was detected only in 11 (36.6%) isolates, 6 (28.5 %) of E. coli and 5(55.5%) of K. pneumoniae isolates respectively. All isolates were susceptible to carbapenems.

Conclusion: The great diversity of ESBL and the prevalences of clinical isolates of E. coli and K. pneumoniae producing these enzymes indicate that this is an important problem in our region. The most active antimicrobial agent against isolates used in this study was carbapenem. It is, therefore strongly recommended to consider carbapenems as the drug of choice for such multi-drug resistant ESBL-producing microorganisms.

Keywords: ESBL; blaSHV gene; E. coli; K. pneumoniae.



1. Cheong HT, Ho WY, Choo QC, Chew CH. β-lactamase gene blaSHV detected in bacteria isolated from retail sushi in Kampar, Malaysia. Biomed Res 2014; 25(1):25–31.

2. Juma BW, Kariuki S, Waiyaki PG, Mutugi MM, Bulimo WD.The prevalence of TEM and SHV genes among Extended-Spectrum Beta-Lactamase-producing Klebsiella pneumoniae and Escherichia coli. Afr J Pharmacol Ther 2016; 5(1):1–7.

3. Harada Y, Morinaga Y, Yamada K, Migiyama Y, Nagaoka K, Uno N, et al. Clinical and Molecular Epidemiology of Extended-Spectrum β-lactamase- Producing Klebsiella pneumoniae and Escherichia Coli in a Japanese Tertiary Hospital. J Med Micro Diagn 2013; 2:127.

4. Altayar MA, Thokar MA, Mohammad MA. Extended spectrum B-lactamase-producing Escherichia coli in clinical isolates in Benghazi, Libia: Phenotypic detection and antimicrobial susceptibility pattern. Medical Journalof Islamic World Academy of Sciences 2012; 20(2):49–6.

5. Dugal S, Purohit H. Antimicrobial Susceptibility Profile and Detection of Extended Spectrum Beta-Lactamase Production by Gram Negative Uropathogens. Int J Pharm PharmSci 2013; 5(4): 434–8.

6. Al-Mayahie SMG. Phenotypic and genotypic comparison of ESBLproduction by Vaginal Escherichia coli isolates from pregnant and non-pregnant women. Ann Clin Microbiol Antimicrob 2013; 12:7.

7. Chaudhary M, Payasi A. Molecular characterization and in vitro susceptibilities of β-lactamase producing Escherichia coli, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus to CSE1034 and other β-lactams. Asian Pac J Trop Med 2014; 7(Suppl 1):217–23.

8. Nakamura T, Komatsu M, Yamasaki K, Fukuda S, Miyamoto Y, Higuchi T, et al. Epidemiology of Escherichia coli, Klebsiella Species, and Proteus mirabilis strains producing extended-spectrum beta-lactamases from clinical samples in the Kinki region of Japan. Am J Cli Pathol 2012; 137(4):620–6.

9. Seyedjavadi SS, Goudarzi M, Sabzehali F. Relation between blaTEM, blaSHV and blaCTX-M genes and acute urinary tract infections. J Acute Dis 2016; 5(1):71–6.

10. Sharma M, Pathak S, Srivastava P. Prevalence and antibiogram of Extended Spectrum β-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp. J Clin Diagn Res 2013 ; 7(10):2173–7.

11. Gulfem E. Comparison of conventional method and automatized vitek system in the detection of extended-spectrum beta-lactamase in Escherichia coli and Klebsiella pneumonia isolates. Afr J Microbiol Res 2013; 7(32):4091– 5.

12. Khanfar HS, Bindayna KM, Senok AC, Botta GA. Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. J Infect Dev Ctries 2009; 3(4):295–9.

13. Gholipour A, Soleimani N, Shokri D, Mobasherizadeh S, Kardi M, Baradaran A. Phenotypic and Molecular Characterization of Extended-Spectrum β-Lactamase Produced by Escherichia coli, and Klebsiella pneumoniae    isolates in an Educational Hospital. Jundishapur       J Microbiol 2014; 7(10):e11758.

14. Navon-Venezia S, Hammer-Munz O, Schwartz D, Turner D, Kuzmenko B, Carmeli Y. Occurrence and Phenotypic Characteristics of Extended-Spectrum β-Lactamases among Members of the Family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and Evaluation of Diagnostic Tests. J Clin Microbiol 2003; 41(1):155–8.

15. Dashti AA, West P, Paton R, Amyes SGB. Characterization of extended-spectrum b-lactamase (ESBL)-producing Kuwait and UK strains identified by the Vitek system, and subsequent comparison of the Vitek system with other commercial ESBL-testing systems using these strains. J Med Microbiol 2006; 55:417–21.

16. Hassan H, Abdalhamid B. Molecular characterization of extended-spectrum beta-lactamase producing Enterobacteriaceae in a Saudi Arabian tertiary hospital. J Infect Dev Ctries 2014; 8(3):282–8.  

17. Batarseh A, Soneah S, Mardeni R, Elmadni K, Noor M, Abu Ashour N. Antibiotic resistance patterns of multidrug resistance and Extend spectrum beta lactamase producing Escherichia coli urinary isolates at Queen Rani AL-Abdullah hospital for children. Jorden ZUMJ 2013; 19 (5):286–93.

18. Robin F, Delmas J, Schweitzer C, Bonnet R. Evaluation of the Vitek-2 extended-spectrum b-lactamase test against non-duplicate strains of Enterobacteriaceae producing a broad diversity of well-characterized b-lactamases. ClinMicrobiol Infect 2008; 14(2):148–54.

19. Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, et al. Extended-Spectrum beta-Lactamases in Klebsiella pneumoniae. Bloodstream Isolates from Seven Countries: Dominance and Widespread Prevalence of SHV- and CTX-M-Type beta-Lactamases. Antimicrob Agents Chemother 2003; 47(11):3554–60.

20. Brin ̃as L, Zarazaga M, S ́aenz Y, Ruiz-Larrea F, Torres C. B-Lactamases in Ampicillin-Resistant Escherichia coli Isolates from Foods, Humans, and Healthy Animals. Antimicrob Agents Chemother 2002; 46(10):3156–63.

21. Hassan M, Alkharsah KR, Alzahrani AJ, Obeid OE , Khamis AH, Diab A. Detection of extended spectrum beta-lactamases-producing isolates and effect of AmpC overlapping. J Infect Dev Ctries 2013; 7(8):618–29.

22. Paterson DL, Ko WC, Von GA, Casellas JM, Mulazimoglu L, Klugman KP. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β -lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39(6):2206–12.

23. Al-Jasser AM. Extended-spectrum beta-lactamases (ESBLs): a global problem. Kuwait Med J 2006; 38(3):171–5.

24. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev 2005; 18:657–86.

25. Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M,Walsh TR, et al. Effects of phenotype and genotype on methods for detection of extended-spectrum-β-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 2007; 45:199–205.

26. Dallal MS, Sabbaghi A, Aghamirzaeie HM, Lari AR, Eshraghian MR, Mehrabad JF, et al. Prevalence of AmpC and SHV β-Lactamases in Clinical Isolates of Escherichia coli From Tehran Hospitals. Jundishapur J Microbiol 2013; 6(2):176–80.

27. Mokaddas EM, Abdulla AA, Shati S, Rotimi VO. The technical aspects and clinical significance of detecting extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary-care hospital in Kuwait. J Chemother 2008; 20:445–51.

28. Perez F, Endimiani A, Hujer KM, Bonomo RA .The continuing challenge of ESBLs. Curr Opin Pharmacol 2007; 7:459–69.

29. Gur D, Hascelik G, Aydin N, Telli M, Gultekin M, Ogulnc D, et al. Antimicrobial resistance in gram-negative hospital isolates: results of the Turkish HITIT-2 Surveillance Study of 2007. J Chemother 2009; 21:383–9.

30. Al-Zarouni M, Senok A, Rashid F, Al-Jesmi SM, Panigrahi D. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates. Med PrincPract 2008; 17:32–6.

31. Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect 2008 ;14 (Suppl 1):159–65.

32. Dagi HT, Al Dulaimi AA, Kus H, Seyhan T, Findik D, Tuncer I, et al. Genotype distribution of extended Spectrum β-Lactamase producing Escherichia coli and Klebsiellapneumoniae. Biomed Res 2015; 26(2):235–8.

33. Kaftandzieva A, Trajkovska-Dokic E, Panovski N. Prevalence And Molecular Characterization Of Extended Spectrum Beta-Lactamases (ESBLs) Producing Escherichia coli and Klebsiella pneumoniae. Biol Med Sci 2011; 32:129–41.

34. Bali EB, Acik L, Sultan N. Phenotypic and molecular characterization of SHV, TEM, CTX-M and extended-spectrum β-lactamase produced by Escherichia coli, Acinetobacterbaumanii and Klebsiella isolates in a Turkish hospital. Afr J Microbiol Res 2010; 4(8):650–4.

35. Oksuz L, Gurler N. Typing of extended-spectrum betalactamases in Escherichia coli and Klebsiellaspp.strains and analysis of plasmid profiles. MikrobiyolBul 2009; 43:183–94.

36. Gur D, Gulay Z, Akan OA, Aktaş Z, Kayacan CB, Cakici O, et al. Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study. Mikrobiyol Bul 2008; 42(4):537–44.

37. Fernandes R, Amador P, Oliveira C, Prudêncio C. Molecular Characterization of ESBL-Producing Enterobacteriaceae in Northern Portugal. The Scientific World Journal 2014; 2014:1–6.

38. Nimri L, Azaizeh B. First Report of Multidrug-Resistant ESBL Producing Urinary Escherichia coli in Jordan. British Microbiol Res J 2012; 2(2):71–81.